Search

Learn how cancer patients benefit from carefully considered design at Memorial Sloan Kettering, from the director of its design team.

… Wednesday, November 20, 2019 People in a waiting room The transfusion areas at MSK facilities, including those at The David H. Koch Center for Cancer Care at Memorial Sloan Kettering, give people easy access to care teams and provide a choice between privacy or socializing with other patients and caregivers

Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing.

… Tuesday, July 28, 2020 Memorial Sloan Kettering Cancer Center (MSK) has been recognized as the number two hospital for cancer care in the nation by U.S. News & World Report in its annual Best Hospitals listing. Since U.S. News & World Report established the prestigious rankings more than 30 years ago

During the AACR COVID-19 and Cancer Meeting, several MSK physicians presented information about providing safe patient care, vaccines, and clinical research.

… Friday, February 12, 2021 At the American Association for Cancer Research (AACR) COVID-19 and Cancer Meeting on February 3-5, 2021, oncology experts from around the world tuned in virtually to discuss the impact of COVID-19 on cancer care. The meeting featured presentations of emerging data in basic,

In February, Harold Varmus' memoir about his life in science was published.

… Sunday, March 1, 2009 Summary In February, Harold Varmus’ memoir about his life in science was published. The Art and Politics of Science, Harold Varmus In February, W. W. Norton & Company published Memorial Sloan Kettering Cancer Center President Harold Varmus’ memoir about his life in science. The

An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center and the National Cancer Institute has identified a new genetic marker of risk for breast cancer. Women with this DNA variation are at a 1.4 times greater risk of developing breast cancer compared to those without the variation.

… Monday, March 3, 2008 An international group of investigators led by scientists at Memorial Sloan Kettering Cancer Center (MSKCC) and the National Cancer Institute has identified a new genetic marker of risk for breast cancer . Women with this DNA variation are at a 1.4 times greater risk of developing

Learn about the different types of benign breast lumps.

… Friday, May 24, 2024 What should you do if you notice a lump in your breast? Don’t panic. See your doctor. “Many lumps turn out to be benign,” says Memorial Sloan Kettering Cancer Center breast radiologist Kimberly N. Feigin, MD , Acting Chief of Breast Radiology at MSK. “But the most important thing

New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for the disease.

… Tuesday, May 20, 2014 Data Supports Routine Tumor Genotyping for Patients with Advanced Lung Cancers; May Improve Survival New data from a study led by Memorial Sloan Kettering physicians that used targeted therapy for patients with the most common type of lung cancer has helped transform treatment for

Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal of Medicine (NEJM). In the comprehensive review article, Drs. Sadelain and June highlight the emerging immunotherapy treatment for hematologic cancers known as CAR T cells, which was developed at MSK. The paper is the first in a series being published by NEJM. Known as Frontiers in Medicine, it will showcase ways that new technologies are influencing contemporary medicine and science.

… Wednesday, July 4, 2018 Immunotherapy pioneers Michel Sadelain, MD, PhD, of Memorial Sloan Kettering Cancer Center (MSK), and Carl June, MD, of the University of Pennsylvania, have published a seminal review of the current landscape of chimeric antigen receptor (CAR) therapy in the New England Journal

Researchers at MSK published updated data today in the New England Journal of Medicine from the ongoing, single-arm Phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with MET exon 14 (METex14) skipping alterations.

… Friday, May 29, 2020 Researchers at Memorial Sloan Kettering Cancer Center (MSK) published updated data today in the New England Journal of Medicine from the ongoing, single-arm phase II VISION study evaluating tepotinib as a single agent in patients with advanced non-small cell lung cancer (NSCLC) with

Longtime donors Fiona and Stanley Druckenmiller have contributed a transformative gift of $100 million to MSK through their foundation. The gift will be used to launch the Fiona and Stanley Druckenmiller Presidential Innovation Fund.

… Tuesday, January 11, 2022 Memorial Sloan Kettering Cancer Center (MSK) today announced the launch of the Fiona and Stanley Druckenmiller Presidential Innovation Fund. The new initiative, made possible by a transformative $100 million gift from the Fiona and Stanley Druckenmiller Foundation, is expected